Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Crofelemer crawled time : 16:20 save search
UPDATED RELEASE: Jaguar Health Enters Exclusive Crofelemer Revenue Sharing Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
Published: 2022-04-01 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -4.62%
H: 0.58%
C: -6.76%
health distribution license crofelemer store
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
Published: 2022-02-16 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -0.76%
H: 1.54%
C: -3.29%
treatment fda health diarrhea crofelemer designation
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Published: 2022-02-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -0.76%
H: 0.75%
C: -8.75%
health drug approval diarrhea crofelemer
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
Published: 2021-12-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: 0.0%
health phase 2 symposium sabcs presentation diarrhea therapy cancer breast cancer initiated crofelemer
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2021-11-19 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 1.72%
H: 6.44%
C: 2.37%
phase 2 diarrhea therapy results cancer topline breast cancer initiated crofelemer
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.